Bernard Golding
Bernard Thomas Golding (* 1941 ) is a British chemist.
Golding graduated from the University of Manchester with a PhD . He is a professor at Newcastle University .
Golding worked for Albert Eschenmoser on the synthesis of vitamin B12 .
He deals with organic synthesis, especially with regard to applications in medicine and biology, for example the development of chemotherapeutic agents against cancer. He is one of the developers of rupacarib (trade name Rubraca), a chemotherapy drug for ovarian cancer (a PARP inhibitor ). Another area of research is radical enzymes and the mechanisms of carcinogenesis by toxic chemical substances.
He has produced over 500 scientific publications and has supervised more than 100 doctoral students. He holds over 60 patents and is co-founder and scientific director of the companies NewChem and BiBerChem Research.
In 2019 he received the Robert Robinson Award . He was also one of the recipients of Cancer Research UK's first Translational Research Prize in 2010 for work on inhibitors of the DNA repair enzyme poly (ADP-ribose) polymerase 1 (PARP). In 2005 he received an honorary doctorate from Stockholm University.
Web links
| personal data | |
|---|---|
| SURNAME | Golding, Bernard |
| ALTERNATIVE NAMES | Golding, Bernard Thomas (full name) |
| BRIEF DESCRIPTION | British chemist |
| DATE OF BIRTH | 1941 |